su011248
Pancreatic Neuroendocrine Tumor
National Cancer Institute (NCI)Phase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Pancreatic Neuroendocrine Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Exelixis | Phase 4 | BBB |
Tak-228 National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 Exelixis | Phase 3 | B |
Atezolizumab Exelixis | Phase 3 | B |
Nab-Sirolimus Aadi Bioscience, Inc. | Phase 2 | CCC |
View all 24 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →